SCHEDULE 13G/A: Morgan Stanley Reduces Stake in 2seventy bio, Inc. Below 5% Threshold

Morgan Stanley has filed an amended Schedule 13G, disclosing that it is no longer a beneficial owner of more than five percent of 2seventy bio, Inc.'s common stock.

Summary

• Morgan Stanley, a Delaware-based entity, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in 2seventy bio, Inc.
• As of May 30, 2025, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the common stock of 2seventy bio, Inc.
• The aggregate amount beneficially owned by Morgan Stanley is now 0.00 shares, representing 0.0% of the class of securities.
• Morgan Stanley previously held a beneficial ownership stake above the 5% threshold, necessitating this amendment to report the reduction.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing reporting a change in beneficial ownership. While a reduction in institutional holding can be interpreted negatively by the market, the document itself is neutral in tone and provides no forward-looking statements or performance metrics.

Negatives

• Morgan Stanley has ceased to be a beneficial owner of more than five percent of 2seventy bio, Inc.'s common stock, indicating a reduction in a significant institutional holding.

Stakeholder Impact

• Shareholders: The reduction in Morgan Stanley's stake below the 5% threshold may be interpreted by the market as a change in investment sentiment from a significant institutional holder, potentially influencing investor perception and trading activity.

Key Dates

Keywords

2seventy bio, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Change